adenine has been researched along with Minimal Disease, Residual in 30 studies
Excerpt | Relevance | Reference |
---|---|---|
" We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients." | 3.11 | Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. ( Aymerich, M; Beà, S; Campo, E; Casanova, M; Cortés-Romera, M; de la Cruz, F; de la Fuente, A; García Sanz, R; Giné, E; González Barca, E; González-López, TJ; Jiménez Ubieto, A; López Jimenez, J; López-Guillermo, A; Marín-Niebla, A; Martín García-Sancho, A; Medina Herrera, A; Muntañola, A; Nadeu, F; Rodríguez, S; Rotger, A; Setoain, X; Terol, MJ, 2022) |
"After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%." | 2.90 | Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019) |
"Advances in the molecular biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and development of molecularly targeted therapies have resulted in treatment innovations." | 2.66 | Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? ( Suzumiya, J; Takizawa, J, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (40.00) | 24.3611 |
2020's | 18 (60.00) | 2.80 |
Authors | Studies |
---|---|
Wierda, WG | 6 |
Allan, JN | 3 |
Siddiqi, T | 2 |
Kipps, TJ | 2 |
Opat, S | 2 |
Tedeschi, A | 3 |
Badoux, XC | 1 |
Kuss, BJ | 2 |
Jackson, S | 2 |
Moreno, C | 2 |
Jacobs, R | 3 |
Pagel, JM | 1 |
Flinn, I | 1 |
Pak, Y | 1 |
Zhou, C | 3 |
Szafer-Glusman, E | 2 |
Ninomoto, J | 3 |
Dean, JP | 2 |
James, DF | 1 |
Ghia, P | 3 |
Tam, CS | 4 |
Giné, E | 1 |
de la Cruz, F | 1 |
Jiménez Ubieto, A | 1 |
López Jimenez, J | 1 |
Martín García-Sancho, A | 1 |
Terol, MJ | 1 |
González Barca, E | 1 |
Casanova, M | 1 |
de la Fuente, A | 1 |
Marín-Niebla, A | 1 |
Muntañola, A | 1 |
González-López, TJ | 1 |
Aymerich, M | 1 |
Setoain, X | 1 |
Cortés-Romera, M | 1 |
Rotger, A | 1 |
Rodríguez, S | 1 |
Medina Herrera, A | 1 |
García Sanz, R | 1 |
Nadeu, F | 1 |
Beà, S | 1 |
Campo, E | 1 |
López-Guillermo, A | 1 |
Huber, H | 1 |
Edenhofer, S | 1 |
von Tresckow, J | 1 |
Robrecht, S | 1 |
Zhang, C | 1 |
Tausch, E | 1 |
Schneider, C | 1 |
Bloehdorn, J | 1 |
Fürstenau, M | 2 |
Dreger, P | 2 |
Ritgen, M | 1 |
Illmer, T | 1 |
Illert, AL | 1 |
Dürig, J | 1 |
Böttcher, S | 2 |
Niemann, CU | 2 |
Kneba, M | 2 |
Fink, AM | 2 |
Fischer, K | 1 |
Döhner, H | 2 |
Hallek, M | 3 |
Eichhorst, B | 2 |
Stilgenbauer, S | 2 |
Barr, PM | 3 |
Trentin, L | 1 |
Bannerji, R | 1 |
Russell, K | 1 |
Kater, AP | 1 |
Levin, MD | 1 |
Dubois, J | 1 |
Kersting, S | 1 |
Enggaard, L | 1 |
Veldhuis, GJ | 1 |
Mous, R | 1 |
Mellink, CHM | 1 |
van der Kevie-Kersemaekers, AF | 1 |
Dobber, JA | 1 |
Poulsen, CB | 1 |
Frederiksen, H | 1 |
Janssens, A | 1 |
Schjødt, I | 1 |
Dompeling, EC | 1 |
Ranti, J | 1 |
Brieghel, C | 1 |
Mattsson, M | 1 |
Bellido, M | 1 |
Tran, HTT | 1 |
Nasserinejad, K | 1 |
Roeker, LE | 1 |
Feldman, TA | 1 |
Soumerai, JD | 1 |
Falco, V | 1 |
Panton, G | 1 |
Dorsey, C | 1 |
Zelenetz, AD | 1 |
Falchi, L | 1 |
Park, JH | 1 |
Straus, DJ | 1 |
Pena Velasquez, C | 1 |
Lebowitz, S | 1 |
Fox, Y | 1 |
Battiato, K | 1 |
Laudati, C | 1 |
Thompson, MC | 1 |
McCarthy, E | 1 |
Kdiry, S | 1 |
Martignetti, R | 1 |
Turpuseema, T | 1 |
Purdom, M | 1 |
Paskalis, D | 1 |
Miskin, HP | 1 |
Sportelli, P | 1 |
Leslie, LA | 1 |
Mato, AR | 3 |
Vallisa, D | 1 |
O'Brien, S | 4 |
Grigg, AP | 1 |
Walker, P | 1 |
Krigsfeld, G | 1 |
Thompson, PA | 2 |
Keating, MJ | 4 |
Ferrajoli, A | 4 |
Jain, N | 4 |
Peterson, CB | 1 |
Garg, N | 2 |
Wang, SA | 1 |
Jorgensen, JL | 1 |
Kadia, TM | 1 |
Bose, P | 2 |
Pemmaraju, N | 2 |
Short, NJ | 1 |
Huang, SJ | 1 |
Gerrie, AS | 1 |
Young, S | 1 |
Tucker, T | 1 |
Bruyere, H | 1 |
Hrynchak, M | 1 |
Galbraith, P | 1 |
Al Tourah, AJ | 1 |
Dueck, G | 1 |
Noble, MC | 1 |
Ramadan, KM | 1 |
Tsang, P | 1 |
Hardy, E | 1 |
Sehn, L | 1 |
Toze, CL | 1 |
Suzumiya, J | 1 |
Takizawa, J | 1 |
Gianfelici, V | 1 |
Levato, L | 1 |
Molica, S | 1 |
Hu, EY | 1 |
Blachly, JS | 1 |
Saygin, C | 1 |
Ozer, HG | 1 |
Workman, SE | 1 |
Lozanski, A | 1 |
Doong, TJ | 1 |
Chiang, CL | 1 |
Bhat, S | 1 |
Rogers, KA | 2 |
Woyach, JA | 2 |
Coombes, KR | 1 |
Jones, D | 1 |
Muthusamy, N | 1 |
Lozanski, G | 2 |
Byrd, JC | 3 |
Huang, Y | 1 |
Ruppert, AS | 1 |
Abruzzo, LV | 1 |
Andersen, BL | 1 |
Awan, FT | 1 |
Bhat, SA | 1 |
Dean, A | 1 |
Lucas, M | 1 |
Banks, C | 1 |
Grantier, C | 1 |
Heerema, NA | 1 |
Maddocks, KJ | 1 |
Valentine, TR | 1 |
Weiss, DM | 1 |
Jones, JA | 1 |
Michallet, AS | 2 |
Letestu, R | 2 |
Le Garff-Tavernier, M | 2 |
Aanei, C | 2 |
Ticchioni, M | 2 |
Dilhuydy, MS | 2 |
Subtil, F | 2 |
Rouille, V | 2 |
Mahe, B | 2 |
Laribi, K | 2 |
Villemagne, B | 2 |
Salles, G | 2 |
Tournilhac, O | 2 |
Delmer, A | 2 |
Portois, C | 2 |
Pegourie, B | 2 |
Leblond, V | 2 |
Tomowiak, C | 2 |
De Guibert, S | 2 |
Orsini Piocelle, F | 1 |
Banos, A | 2 |
Carassou, P | 2 |
Cartron, G | 3 |
Fornecker, LM | 2 |
Ysebaert, L | 2 |
Dartigeas, C | 2 |
Truchan-Graczyk, M | 1 |
Vilque, JP | 2 |
Aurran, T | 2 |
Cymbalista, F | 2 |
Lepretre, S | 2 |
Levy, V | 2 |
Nguyen-Khac, F | 2 |
Feugier, P | 2 |
Le Gouill, S | 1 |
Morschhauser, F | 1 |
Chiron, D | 1 |
Bouabdallah, K | 1 |
Casasnovas, O | 1 |
Bodet-Milin, C | 1 |
Ragot, S | 1 |
Bossard, C | 1 |
Nadal, N | 1 |
Herbaux, C | 1 |
Tessoulin, B | 1 |
Tchernonog, E | 1 |
Rossi, C | 1 |
McCulloch, R | 1 |
Gastinne, T | 1 |
Callanan, MB | 1 |
Rule, S | 1 |
Lu, P | 1 |
Wang, S | 1 |
Franzen, CA | 1 |
Venkataraman, G | 1 |
McClure, R | 1 |
Li, L | 1 |
Wu, W | 1 |
Niu, N | 1 |
Sukhanova, M | 1 |
Pei, J | 1 |
Baldwin, DA | 1 |
Nejati, R | 1 |
Wasik, MA | 1 |
Khan, N | 1 |
Tu, Y | 1 |
Gao, J | 1 |
Chen, Y | 1 |
Ma, S | 1 |
Larson, RA | 1 |
Wang, YL | 1 |
Cheson, BD | 1 |
Wang, XV | 1 |
Hanson, CA | 1 |
Tschumper, RC | 1 |
Lesnick, CE | 1 |
Braggio, E | 1 |
Paietta, EM | 1 |
Barrientos, JC | 1 |
Leis, JF | 1 |
Zhang, CC | 1 |
Coutre, SE | 2 |
Cashen, AF | 1 |
Singh, AK | 1 |
Mullane, MP | 1 |
Erba, H | 1 |
Stone, R | 1 |
Litzow, MR | 1 |
Tallman, MS | 1 |
Shanafelt, TD | 1 |
Kay, NE | 1 |
Winqvist, M | 1 |
Palma, M | 1 |
Heimersson, K | 1 |
Mellstedt, H | 1 |
Österborg, A | 1 |
Lundin, J | 1 |
Krämer, I | 1 |
Dietrich, S | 1 |
Zeis, M | 1 |
Stadler, M | 1 |
Bittenbring, J | 1 |
Uharek, L | 1 |
Scheid, C | 1 |
Hegenbart, U | 1 |
Ho, A | 1 |
Schmitz, N | 1 |
Collett, L | 1 |
Howard, DR | 1 |
Munir, T | 1 |
McParland, L | 1 |
Oughton, JB | 1 |
Rawstron, AC | 1 |
Hockaday, A | 1 |
Dimbleby, C | 1 |
Phillips, D | 1 |
McMahon, K | 1 |
Hulme, C | 1 |
Allsup, D | 1 |
Bloor, A | 1 |
Hillmen, P | 2 |
Anderson, MA | 1 |
Pott, C | 1 |
Agarwal, R | 1 |
Handunnetti, S | 1 |
Hicks, RJ | 1 |
Burbury, K | 1 |
Turner, G | 1 |
Di Iulio, J | 1 |
Bressel, M | 1 |
Westerman, D | 1 |
Lade, S | 1 |
Dreyling, M | 1 |
Dawson, SJ | 1 |
Dawson, MA | 1 |
Seymour, JF | 1 |
Roberts, AW | 1 |
Burger, JA | 2 |
Sivina, M | 1 |
Kim, E | 1 |
Kadia, T | 2 |
Estrov, Z | 3 |
Nogueras-Gonzalez, GM | 1 |
Huang, X | 1 |
Jorgensen, J | 2 |
Li, J | 1 |
Cheng, M | 1 |
Clow, F | 2 |
Ohanian, M | 2 |
Andreeff, M | 1 |
Mathew, T | 1 |
Thompson, P | 2 |
Kantarjian, H | 2 |
Keating, M | 1 |
Burger, J | 1 |
Borthakur, G | 1 |
Takahashi, K | 1 |
Fowler, N | 1 |
Konopleva, M | 1 |
Alvarado, Y | 1 |
Yilmaz, M | 1 |
DiNardo, C | 1 |
Jabbour, E | 1 |
Sasaki, K | 1 |
Kanagal-Shamanna, R | 1 |
Patel, K | 1 |
Wang, X | 2 |
Sondermann, K | 1 |
Cruz, N | 1 |
Wei, C | 1 |
Ayala, A | 1 |
Plunkett, W | 1 |
Gandhi, V | 1 |
Wierda, W | 1 |
Orsini, F | 1 |
Truchan Graczyk, M | 1 |
O'Brien, SM | 1 |
Xiao, L | 1 |
Ryan, CE | 1 |
Sahaf, B | 1 |
Logan, AC | 1 |
Brown, JR | 1 |
Dyer, MJ | 1 |
Jaglowski, S | 1 |
Rezvani, AR | 1 |
Styles, L | 1 |
Miklos, DB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT02910583] | Phase 2 | 323 participants (Actual) | Interventional | 2016-09-28 | Active, not recruiting | ||
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma[NCT02682641] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-05-18 | Active, not recruiting | ||
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations[NCT03226301] | Phase 2 | 230 participants (Anticipated) | Interventional | 2017-06-23 | Active, not recruiting | ||
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2015-08-03 | Active, not recruiting | ||
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898] | Phase 2 | 135 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients[NCT02558816] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2015-10-14 | Active, not recruiting | ||
Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia[NCT00281983] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)[NCT02471391] | Phase 2 | 37 participants (Actual) | Interventional | 2015-07-22 | Active, not recruiting | ||
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)[NCT02007044] | Phase 2 | 208 participants (Anticipated) | Interventional | 2013-12-06 | Active, not recruiting | ||
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02756897] | Phase 2 | 234 participants (Actual) | Interventional | 2016-07-07 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 55.9 |
FD Cohort: All Treated | 55.3 |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 24 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 96.1 |
FD Cohort: All Treated | 94.7 |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to time of death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 97.7 |
FD Cohort: All Treated | 98.1 |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of PFS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Median) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 96.2 |
FD Cohort: All Treated | 94.8 |
ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 95.6 |
FD Cohort: All Treated | 96.2 |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort: All Treated | 94.1 |
DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia [IWCLL] criteria [Halleck et al]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time. (NCT02910583)
Timeframe: 1 year after randomization
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 62.8 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 72.1 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 60.5 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 74.2 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 56.3 |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of DOR at 36 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 94.7 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 96.7 |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 99.4 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of PFS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 95.6 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 96.7 |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 97.0 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 88.5 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | L/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 833 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | 1/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 0.132 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng*h/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 48993 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | L/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 8.16 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 3034 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | hours (Median) |
---|---|
MRD Cohort: All Treated | 6.00 |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 90.0 |
MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB. (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) | ||
---|---|---|---|
BM or PB | BM | PB | |
FD Cohort, Non-Del 17p Population: All Treated | 78.7 | 61.8 | 76.5 |
FD Cohort: All Treated | 78.6 | 59.7 | 76.7 |
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the FD cohort was 13.3 months for ibrutinib and 11.1 for venetoclax.
Intervention | percentage of participants (Number) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Any Grade >=3 TEAE | Any Ibrutinib (Ibr)-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Venetoclax (Ven)-Related TEAE | Any Grade >=3 Venetoclax-Related TEAE | Any TEAE Leading to Ibr or Ven Discontinuation | Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | Any TEAE Leading to Ibr or Ven Dose Reduction | Any TEAE Leading to Ibr Only Dose Reduction | Any TEAE Leading to Ven Only Dose Reduction | Any TEAE Leading to Both Ibr and Ven Dose Reduction | Any SAE | Any Grade >= 3 SAE | Any SAE Related to Ibr or Ven | Any Ibr-related SAE | Any Ven-related SAE | Fatal TEAE | Major Hemorrhage TEAE | Grade >= 3 Major Hemorrhage TEAE | Major Hemorrhage SAE | |
FD Cohort: All Treated | 99.4 | 62.3 | 92.5 | 44.7 | 84.3 | 44.7 | 5.0 | 3.1 | 0 | 1.9 | 20.8 | 5.7 | 11.3 | 3.8 | 22.6 | 19.5 | 13.2 | 11.3 | 8.2 | 0.6 | 1.9 | 1.3 | 1.3 |
"MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB.~This rate is calculated in the uMRD Not Confirmed randomized population during the period from randomization date and before any reintroduced treatment." (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) | ||
---|---|---|---|
PB or BM | BM | PB | |
MRD Cohort: All Treated | 81.1 | 76.8 | 79.3 |
MRD Cohort/uMRD Not Confirmed: All Participants | 63.5 | 54.0 | 58.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 51.6 | 41.9 | 48.4 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 75.0 | 65.6 | 68.8 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the MRD cohort was 28.7 months for ibrutinib and 15.4 for venetoclax.
Intervention | percentage of participants (Number) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Any Grade >=3 TEAE | Any Ibrutinib (Ibr)-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Venetoclax (Ven)-Related TEAE | Any Grade >=3 Venetoclax-Related TEAE | Any TEAE Leading to Ibr or Ven Discontinuation | Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | Any TEAE Leading to Ibr or Ven Dose Reduction | Any TEAE Leading to Ibr Only Dose Reduction | Any TEAE Leading to Ven Only Dose Reduction | Any TEAE Leading to Both Ibr and Ven Dose Reduction | Any SAE | Any Grade >= 3 SAE | Any SAE Related to Ibr or Ven | Any Ibr-related SAE | Any Ven-related SAE | Fatal TEAE | Major Hemorrhage TEAE | Grade >= 3 Major Hemorrhage TEAE | Major Hemorrhage SAE | |
MRD Cohort: All Treated | 100.0 | 73.8 | 94.5 | 57.9 | 80.5 | 44.5 | 12.8 | 7.3 | 1.2 | 4.3 | 24.4 | 14.6 | 5.5 | 4.3 | 31.1 | 26.2 | 18.3 | 15.9 | 5.5 | 0.6 | 2.4 | 1.8 | 2.4 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 | 79.1 | 93.0 | 55.8 | 86.0 | 51.2 | 4.7 | 2.3 | 2.3 | 0 | 20.9 | 14.0 | 4.7 | 2.3 | 27.9 | 25.6 | 16.3 | 11.6 | 4.7 | 0 | 2.3 | 2.3 | 2.3 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 | 65.1 | 93.0 | 48.8 | 76.7 | 34.9 | 0 | 0 | 0 | 0 | 23.3 | 9.3 | 11.6 | 2.3 | 18.6 | 16.3 | 11.6 | 9.3 | 7.0 | 0 | 0 | 0 | 0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 100.0 | 71.0 | 96.8 | 61.3 | 80.6 | 45.2 | 9.7 | 9.7 | 0 | 0 | 22.6 | 16.1 | 0 | 6.5 | 35.5 | 29.0 | 22.6 | 19.4 | 9.7 | 3.2 | 3.2 | 3.2 | 3.2 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 | 75.0 | 93.8 | 62.5 | 96.9 | 56.3 | 12.5 | 3.1 | 0 | 9.4 | 31.3 | 21.9 | 3.1 | 6.3 | 37.5 | 28.1 | 18.8 | 18.8 | 3.1 | 0 | 6.3 | 3.1 | 6.3 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng*h/mL (Geometric Mean) | |
---|---|---|
AUC0-24h | AUClast | |
MRD Cohort: All Treated | 504 | 480 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | hours (Median) | ||
---|---|---|---|
tmax | tlast | t1/2term | |
MRD Cohort: All Treated | 2.00 | 24.0 | 5.30 |
2 reviews available for adenine and Minimal Disease, Residual
Article | Year |
---|---|
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compou | 2020 |
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2020 |
17 trials available for adenine and Minimal Disease, Residual
Article | Year |
---|---|
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Het | 2021 |
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Mantle-Cell; | 2022 |
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2022 |
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2022 |
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Heterocyclic Compou | 2022 |
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2020 |
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Com | 2021 |
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, | 2021 |
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Alemtuzumab; Antineoplastic Combined Chemotherap | 2018 |
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
Topics: Adenine; Adult; Aged; Alemtuzumab; Allografts; Antineoplastic Agents, Immunological; Combined Modali | 2017 |
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chem | 2017 |
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineo | 2018 |
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2019 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr | 2019 |
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Topics: Adenine; Adult; Aged; B-Lymphocytes; Chimerism; Cohort Studies; Female; Germinal Center; Graft vs Ho | 2016 |
11 other studies available for adenine and Minimal Disease, Residual
Article | Year |
---|---|
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2022 |
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cr | 2022 |
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2023 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb | 2019 |
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Co | 2019 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Col | 2020 |
LC-FACSeq is a method for detecting rare clones in leukemia.
Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mu | 2020 |
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2021 |
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Female; Flow Cytometry; | 2020 |
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm | 2019 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |